Literature DB >> 12932441

Transforming growth factor beta1 overexpression in the nigrostriatal system increases the dopaminergic deficit of MPTP mice.

Amelia Sánchez-Capelo1, Philippe Colin, Bernard Guibert, Nicole Faucon Biguet, Jacques Mallet.   

Abstract

Idiopathic Parkinson's disease (PD) is characterized by mesencephalic dopaminergic neuron cell death and striatal dopamine (DA) depletion. The factors involved in the pathogenesis of the disease are still unknown. Transforming growth factor beta1 (TGFbeta1) is increased in the striatum of patients with PD. However, the effect of this increase is not known. Here, we show that overexpression of TGFbeta1, by recombinant adenovirus TGFbeta1 gene transfer, in the mesostriatal system of an MPTP mouse model of PD decreased the number of mesencephalic dopaminergic neurons. This effect also involved more extensive DA depletion in the striatum. Striatal enkephalin mRNA levels are augmented, suggesting a decrease in dopaminergic transmission to the postsynaptic target. In the absence of MPTP, TGFbeta1 greatly decreased the number of dopaminergic neurons in the ventral mesencephalon of fully mature mice. These results show that an increase in TGFbeta1 levels aggravate the parkinsonian status of MPTP mice and may therefore be a risk factor for the development of PD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12932441     DOI: 10.1016/s1044-7431(03)00081-2

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  8 in total

1.  Deficiency in Neuronal TGF-β Signaling Leads to Nigrostriatal Degeneration and Activation of TGF-β Signaling Protects against MPTP Neurotoxicity in Mice.

Authors:  Ina Tesseur; Andy Nguyen; Betty Chang; Lulin Li; Nathaniel S Woodling; Tony Wyss-Coray; Jian Luo
Journal:  J Neurosci       Date:  2017-03-31       Impact factor: 6.167

Review 2.  TGF-β as a Key Modulator of Astrocyte Reactivity: Disease Relevance and Therapeutic Implications.

Authors:  Jian Luo
Journal:  Biomedicines       Date:  2022-05-23

3.  Dopamine and α-synuclein dysfunction in Smad3 null mice.

Authors:  Silvia Tapia-González; Rosa M Giráldez-Pérez; M Isabel Cuartero; M José Casarejos; M Ángeles Mena; Xiao-Fan Wang; Amelia Sánchez-Capelo
Journal:  Mol Neurodegener       Date:  2011-10-13       Impact factor: 14.195

4.  A Neuron-Glial Trans-Signaling Cascade Mediates LRRK2-Induced Neurodegeneration.

Authors:  Elie Maksoud; Edward H Liao; A Pejmun Haghighi
Journal:  Cell Rep       Date:  2019-02-12       Impact factor: 9.423

Review 5.  Models of α-synuclein aggregation in Parkinson's disease.

Authors:  Rosa Giráldez-Pérez; Mónica Antolín-Vallespín; María Muñoz; Amelia Sánchez-Capelo
Journal:  Acta Neuropathol Commun       Date:  2014-12-13       Impact factor: 7.801

Review 6.  Microglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's Disease-Lessons from Transgenic Mice.

Authors:  Venissa Machado; Tanja Zöller; Abdelraheim Attaai; Björn Spittau
Journal:  Int J Mol Sci       Date:  2016-01-26       Impact factor: 5.923

7.  Altered Expression of Matrix Metalloproteinases and Their Endogenous Inhibitors in a Human Isogenic Stem Cell Model of Huntington's Disease.

Authors:  Swati Naphade; Alexander Embusch; Kuruwitage Lakshika Madushani; Karen L Ring; Lisa M Ellerby
Journal:  Front Neurosci       Date:  2018-02-05       Impact factor: 4.677

Review 8.  TGF-β/Smad3 Signalling Modulates GABA Neurotransmission: Implications in Parkinson's Disease.

Authors:  Mª Dolores Muñoz; Nerea de la Fuente; Amelia Sánchez-Capelo
Journal:  Int J Mol Sci       Date:  2020-01-16       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.